Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Q12021
Sort By
Newest First
1 / 1
Lyophilization
Shorten Time to Market with New Data-Driven Lyophilization Process
Jeff Tremain
AbbVie Contract Manufacturing
PAO-03-21-CL-07
Mar 29, 2021
Clinical Trial Logistics
Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies
Mark Woolf
Catalent
PAO-03-21-CL-06
Mar 22, 2021
Business Development
Q: How are you growing your business development activities in the absence of conventional trade shows and other traditional business development/marketing activities?
Pharma's Almanac
PAO-03-21-NI-02
Mar 16, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01
Mar 16, 2021
Tissue Models
Accurately Recapitulating Environmental Niches in In Vitro Models of the Intestine
Liz Boazak, Ph.D.
Altis Biosystems
PAO-03-21-CL-01
Mar 11, 2021
Facility Design
Cell Therapy Facility Design Synopsis: Horizontal vs. Vertical
Brian Peasley
IPS-Integrated Project Services, LLC
PAO-03-21-CL-02
Mar 08, 2021
Tissue Models
Developing a Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity
Ron Laethem, Ph.D.
Altis Biosystems
PAO-02-21-CL-04
Feb 18, 2021
Process Intensification
Factory of the Future Will Be a Convergence of Digital and Bioprocessing Technologies
Vikas Revankar
MilliporeSigma
PAO-02-21-CL-03
Feb 17, 2021
Nitrosamine
Supporting Drug Manufacturers with Emprove® Nitrosamine Declarations
Ulrich Reichert, M.D.R.A.
MilliporeSigma
PAO-02021-CL-05
Feb 10, 2021
Chemistry, Manufacturing, and Controls
Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization
Matthew Rota; Lisa Caralli; Jim Spavins
Catalent
PAO-01-21-CL-05
Feb 05, 2021
Cell Therapy
Economically Viable, Same-Day Autologous Cell Therapies
Gregory Frost, Ph.D.; Sid Kerkar, M.D.
EXUMA Biotechnology
PAO-01-21-CL-06
Feb 04, 2021
Tissue Models
Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro
Bailey Zwarycz, Ph.D
Altis Biosystems
PAO-02-21-CL-01
Feb 04, 2021
Process Development
Innovative Approach to Process Development
Gerhard Noessner, Ph.D.
Fareva
PAO-02-21-CL-02
Feb 03, 2021
Gene Therapy
Beyond 2020: Looking into the Crystal Ball for Gene Therapy
Ratish Krishnan
MilliporeSigma
PAO-01-21-CL-03
Feb 01, 2021
Tissue Models
The Power of RepliGut In Vitro Intestinal Stem Cell Models
Bailey Zwarycz, Ph.D
Altis Biosystems
PA1081
Jan 26, 2021
HPAPI
A Successful Approach for Managing Unexpected Increases in Potency for HPAPIs
Daniela Kovats
Fareva
PAO-01-21-CL-01
Jan 11, 2021
Cell Therapy
Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology
Catalent
PAO-12-20-CL-01
Dec 16, 2020
1 / 1
